Giant axonal neuropathy is a rare, autosomal recessive neurodegenerative disease of both the peripheral nervous system (PNS) and the central nervous system (CNS). It is one of the inherited leukodystrophies.
Approximately 50 affected families have been reported in the literature; the prevalence is unknown. Of note, giant axonal neuropathy is often reported in the context of parental consanguinity 1-3.
Children typically presents in infancy (often age 3 years) with motor sensory neuropathy in the absence of prodromal signs or symptoms. The CNS is affected later in disease progression, which is demonstrated by cerebellar ataxia, cognitive dysfunction, epilepsy and pyramidal insufficiency 4-6. Of note, kinky hair is often reported.
Mutations in both alleles of the giaxonin gene on chromosome 16 cause large accumulations of neurofilaments, axonal distention ("giant" axons), and degeneration of the myelin sheath 7. The exact mechanism of pathogenesis is unclear; however, giaxonin is thought to have a role in neurofilament degradation as part of an E3 ubiquitin ligase complex 7.
A leukodystropy pattern is often observed on MRI. Specifically, T2/FLAIR-weighted images will show periventricular white matter hyperintensity. In addition, T2/FLAIR-weighted images show hyperintensities diffusely within the cerebellum and cerebrum. Of the latter, the deep brain structure, particularly the basal ganglia, are often abnormal 8,9.
Treatment and prognosis
Treatment focuses on symptom control. The severe and rapidly progressive nature of giant axonal neuropathy unfortunately contributes to death in young adulthood - often by the 30th decade - in the majority of affected individuals 4.
History and etymology
Interestingly, "neuropathy" classically refers to a disease of the PNS only. As GAN also affects the CNS, "giant axonal neurodegeneration" has been proposed as a more appropriate name 4.
- 1. Ouvrier RA, Prineas J, Walsh JC, Reye RD, McLeod JG. Giant axonal neuropathy -- a third case. (1974) Proceedings of the Australian Association of Neurologists. 11: 137-44. Pubmed
- 2. Coscia L, Causa P, Giuliani E, Nunziata A. Pharmacological properties of new neuroleptic compounds. (1975) Arzneimittel-Forschung. 25 (9): 1436-42. Pubmed
- 3. Gambarelli D, Hassoun J, Pellissier JF, Livet MO, Pinsard N, Toga M. Giant axonal neuropathy. Involvement of peripheral nerve, myenteric plexus and extra-neuronal area. (1977) Acta neuropathologica. 39 (3): 261-9. Pubmed
- 4. Bethany L. Johnson‐Kerner, Lisa Roth, J. Palmer Greene, Hynek Wichterle, Douglas M. Sproule. Giant axonal neuropathy: An updated perspective on its pathology and pathogenesis. (2014) Muscle & Nerve. 50 (4): 467. doi:10.1002/mus.24321 - Pubmed
- 5. Hentati F, Hentati E, Amouri R. Giant axonal neuropathy. (2013) Handbook of clinical neurology. 115: 933-8. doi:10.1016/B978-0-444-52902-2.00052-7 - Pubmed
- 6. Gregor Kuhlenbäumer, Vincent Timmerman, Pascale Bomont. Giant Axonal Neuropathy. (2014) Pubmed
- 7. Kang JJ, Liu IY, Wang MB, Srivatsan ES. A review of gigaxonin mutations in giant axonal neuropathy (GAN) and cancer. (2016) Human genetics. 135 (7): 675-84. doi:10.1007/s00439-016-1659-5 - Pubmed
- 8. Garg M, Kulkarni SD, Hegde AU, Desai M, Sayed RJ. Giant Axonal Neuropathy: Clinical, Radiological, and Genetic Features. (2018) Annals of Indian Academy of Neurology. 21 (4): 304-308. doi:10.4103/aian.AIAN_82_18 - Pubmed
- 9. Israni A, Chakrabarty B, Gulati S, Mohamed A, Kumar A, Sable MN, Suri V. Giant axonal neuropathy: a clinicoradiopathologic diagnosis. (2014) Neurology. 82 (9): 816-7. doi:10.1212/WNL.0000000000000177 - Pubmed
Related Radiopaedia articles
White matter disorders
- white matter
- normal myelination
white matter disorders
- anti-MOG associated encephalomyelitis
- Guillain-Barré syndrome (GBS)
- chronic inflammatory demyelinating polyneuropathy (CIDP)
- transverse myelitis
- tumefactive demyelinating lesions
- acute disseminated encephalomyelitis (ADEM)
- acute hemorrhagic encephalomyelitis (AHEM)
- neuromyelitis optica (NMO) (Devic disease)
multiple sclerosis (MS)
McDonald diagnostic criteria for MS (current 2017 revision)
- previous 2016 MAGNIMS consensus
- McDonald diagnostic criteria for MS (current 2017 revision)
- radiologically isolated syndrome (RIS)
- clinically isolated syndrome (CIS)
- early-onset neuronal degenerative disorders
- GM1 & GM2 gangliosidoses (e.g. Tay Sachs disease)
- giant axonal neuropathy
- hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC)
- hypomyelination with congenital cataract
- leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation
- hypomyelination with brainstem and spinal cord involvement and leg spasticity
- Pol III-related leukodystrophies
- early-onset neuronal degenerative disorders
- myelin disorders
- myelin vacuolisation
- adult-onset autosomal dominant leukodystrophy
- cerebrotendinous xanthomathosis
- cystic leukoencephalopathy without megalencephaly
- L-2-hydroxyglutaric aciduria
- lysosomal storage diseases
- peroxisomal disorders
- Sjögren-Larsson syndrome